Details and outcomes of a large cohort of MOG-IgG associated optic neuritis.
暂无分享,去创建一个
H. Moss | E. Sotirchos | S. Pittock | E. Vasileiou | E. Eggenberger | M. T. Bhatti | A. Arnold | E. Flanagan | Amy Kunchok | I. Lotan | M. Hellmann | H. Stiebel-Kalish | A. Wilf-Yarkoni | A. D. Henderson | Alvaro J. Mejia-Vergara | Tanyatuth Padungkiatsagul | Sepideh Jamali | D. Hodge | Amrita-Amanda D Vuppala | Nicolás Seleme | L. Bonelli | Nanthaya Tisavipat | John J. Chen | Marie Di Nome | A. J. Mejia-Vergara | Marie A. Di Nome | M. Bhatti | Adi Wilf-Yarkoni
[1] J. Pruvo,et al. Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss , 2022, Neurology: Neuroimmunology & Neuroinflammation.
[2] B. Chwalisz,et al. MRI Characteristics of NMO, MOG and MS Related Optic Neuritis , 2020, Seminars in ophthalmology.
[3] S. Saidha,et al. AQP4-IgG and MOG-IgG Related Optic Neuritis—Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis , 2020, Frontiers in Neurology.
[4] A. Vosoughi,et al. Resolution of myelin oligodendrocyte glycoprotein (MOG)-IgG optic neuritis without treatment. , 2020, Multiple sclerosis and related disorders.
[5] D. Hodge,et al. Population based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. , 2020, American journal of ophthalmology.
[6] Jacqueline Palace,et al. Prodromal headache in MOG-antibody positive optic neuritis. , 2020, Multiple sclerosis and related disorders.
[7] John J. Chen,et al. Clinical Characteristics and Treatment of MOG-IgG–Associated Optic Neuritis , 2019, Current Neurology and Neuroscience Reports.
[8] John J. Chen,et al. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. , 2019, Current opinion in neurology.
[9] M. Bach,et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? , 2019, Neurology: Neuroimmunology & Neuroinflammation.
[10] T. Siepman,et al. The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults , 2019, Multiple sclerosis.
[11] Quangang Xu,et al. Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: A cohort study in China , 2019, Journal of the Neurological Sciences.
[12] M. Etemadifar,et al. Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: Clinical course and treatment outcome. , 2019, Multiple sclerosis and related disorders.
[13] Quangang Xu,et al. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis , 2019, Journal of the Neurological Sciences.
[14] B. Weinshenker,et al. Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. , 2018, American journal of ophthalmology.
[15] J. A. Fraser,et al. Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial , 2018, JAMA neurology.
[16] John J. Chen,et al. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4–IgG in Patients in the Optic Neuritis Treatment Trial , 2018, JAMA ophthalmology.
[17] T. Kezuka,et al. Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis , 2018, Japanese Journal of Ophthalmology.
[18] Jacqueline Palace,et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study , 2017, Brain : a journal of neurology.
[19] V. Fung,et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[20] A. Petzold,et al. Time is vision in recurrent optic neuritis , 2017, Brain Research.
[21] B. Brochet,et al. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France , 2017, Journal of Neurology.
[22] F. Paul,et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome , 2016, Journal of Neuroinflammation.
[23] T. Nakazawa,et al. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica , 2016, Journal of Neuroimmunology.
[24] V. Fung,et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis , 2016, Multiple sclerosis.
[25] T. Nakazawa,et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[26] M. Kupersmith,et al. Optic neuritis: correlation of pain and magnetic resonance imaging. , 2003, Ophthalmology.
[27] R. Beck,et al. Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. , 1993, Archives of ophthalmology.
[28] Neil R. Miller,et al. A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis , 1992 .
[29] John J. Chen,et al. Optic Neuritis In the Era of Biomarkers. , 2019, Survey of ophthalmology.
[30] Xinghuai Sun,et al. Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China , 2017, Journal of Neurology.